Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease - PubMed (original) (raw)
Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease
G M Campos et al. Arch Surg. 2001 Nov.
Abstract
Hypothesis: Risk factors for the presence and extent of Barrett esophagus (BE) can be identified in patients with gastroesophageal reflux disease (GERD).
Design: Case-comparison study.
Setting: University tertiary referral center.
Patients: Five hundred two consecutive patients with GERD documented by 24-hour esophageal pH monitoring and with complete demographic, endoscopic, and physiological evaluation, divided in groups according to the presence and extent of BE (328 patients without BE and 174 with BE [67 short-segment BE and 107 long-segment BE]).
Main outcome measures: Clinical, endoscopic, and physiological data, studied by multivariate analysis, to identify the independent predictors of the presence and extent of BE.
Results: Seven factors were identified as predictors of BE. They were abnormal bile reflux (odds ratio [OR], 4.2; 95% confidence interval [CI], 1.9-9.7), hiatal hernia larger than 4 cm (OR, 4.1; 95% CI, 2.1-8.0), a defective lower esophageal sphincter (OR, 2.7; 95% CI, 1.4-5.4), male sex (OR, 2.6; 95% CI, 1.6-4.3), defective distal esophageal contraction (OR, 2.2; 95% CI, 1.4-3.5), abnormal number of reflux episodes lasting longer than 5 minutes (OR, 2.2; 95% CI, 1.1-4.6), and GERD symptoms lasting for more than 5 years (OR, 2.1; 95% CI, 1.4-3.2). Only abnormal bile reflux (OR, 4.8; 95% CI, 1.7-13.2) was identified as a predictor of short-segment BE (baseline, no BE). Three factors were identified as predictors of long-segment BE (baseline short-segment BE). They were hiatal hernia larger than 4 cm (OR, 17.8; 95% CI, 4.1-76.6), a defective lower esophageal sphincter (OR, 16.9; 95% CI, 1.6-181.4), and an abnormal longest reflux episode (OR, 8.1; 95% CI, 2.8-24.0).
Conclusions: Among patients with GERD, specific factors are associated with the presence and extent of BE. Elimination of reflux with an antireflux operation in patients with 1 or more of these factors may prevent the future development of BE.
Similar articles
- Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy.
Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P. Balasubramanian G, et al. Am J Gastroenterol. 2012 Nov;107(11):1655-61. doi: 10.1038/ajg.2012.299. Epub 2012 Oct 2. Am J Gastroenterol. 2012. PMID: 23032983 - Risk factors in the development of esophageal adenocarcinoma.
Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, Baumgart DC. Pohl H, et al. Am J Gastroenterol. 2013 Feb;108(2):200-7. doi: 10.1038/ajg.2012.387. Epub 2012 Dec 18. Am J Gastroenterol. 2013. PMID: 23247577 - Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance.
Hoppo T, Komatsu Y, Jobe BA. Hoppo T, et al. Dis Esophagus. 2014 Aug;27(6):530-7. doi: 10.1111/j.1442-2050.2012.01446.x. Epub 2012 Oct 26. Dis Esophagus. 2014. PMID: 23107023 - Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
Shaheen N, Ransohoff DF. Shaheen N, et al. JAMA. 2002 Apr 17;287(15):1972-81. doi: 10.1001/jama.287.15.1972. JAMA. 2002. PMID: 11960540 Review. - Pathogenesis of gastroesophageal reflux and Barrett esophagus.
Buttar NS, Falk GW. Buttar NS, et al. Mayo Clin Proc. 2001 Feb;76(2):226-34. doi: 10.1016/S0025-6196(11)63134-0. Mayo Clin Proc. 2001. PMID: 11213315 Review.
Cited by
- Effect of "white diet" during bile monitoring with Bilitec 2000 on esophageal pH-metry in patients with gastroesophageal reflux disease.
Gutschow CA, Bollschweiler E, Schröder W, Collet P, Collard JM, Hölscher AH. Gutschow CA, et al. J Gastrointest Surg. 2005 Apr;9(4):508-13. doi: 10.1016/j.gassur.2004.09.035. J Gastrointest Surg. 2005. PMID: 15797232 - Reflux, Barrett's, and adenocarcinoma of the esophagus: can we disrupt the pathway?
DeMeester SR. DeMeester SR. J Gastrointest Surg. 2010 Jun;14(6):941-5. doi: 10.1007/s11605-009-1146-6. Epub 2010 Jan 22. J Gastrointest Surg. 2010. PMID: 20094815 No abstract available. - Antireflux Surgery and Barrett's Esophagus: Myth or Reality?
Herbella FAM, Schlottmann F, Patti MG. Herbella FAM, et al. World J Surg. 2018 Jun;42(6):1798-1802. doi: 10.1007/s00268-017-4394-8. World J Surg. 2018. PMID: 29264726 - Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy.
Wolfsen HC, Hemminger LL, DeVault KR. Wolfsen HC, et al. BMC Gastroenterol. 2004 Aug 25;4:18. doi: 10.1186/1471-230X-4-18. BMC Gastroenterol. 2004. PMID: 15327696 Free PMC article. - Increasing incidence of Barrett's oesophagus in the general population.
van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. van Soest EM, et al. Gut. 2005 Aug;54(8):1062-6. doi: 10.1136/gut.2004.063685. Epub 2005 Apr 27. Gut. 2005. PMID: 15857935 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical